Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions

Trial Profile

A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects With de Novo Native Coronary Artery Lesions

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jul 2019

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ABSORB-III; ABSORB-RCT
  • Sponsors Abbott Vascular
  • Most Recent Events

    • 12 Jun 2019 Status changed from active, no longer recruiting to completed.
    • 07 Nov 2018 Planned End Date changed from 1 Sep 2021 to 1 Apr 2019.
    • 25 Sep 2018 Results reporting influence of procedural technique on Everolimus-Eluting Stent outcomes within the ABSORB trials (ABSORB II, ABSORB III, ABSORB China and ABSORB Japan) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top